State Street My2027 Corporate Bond ETFMYCG

State Street’s MYCG ETF is a 2027-maturity corporate bond fund wrapped in enough marketing fluff to choke a pension committee. The fund’s mandate is simple: track the ICE BofA 2027 Maturity BBB US Corporate Index, which is a mouthful that boils down to “bonds maturing in 2027, rated BBB, issued by US corporates.” The index is licensed from S&P Dow Jones Indices LLC, and State Street Global Advisors (now State Street Investment Management) is the one holding the bag and charging the fee. The fund’s expense ratio sits at 0.08%, which is the corporate equivalent of paying a concierge to stamp your bond application.

As of the latest fund-finder page, MYCG is listed on Nasdaq and is part of State Street’s fixed-income ETF suite, which the issuer describes as offering “wide access to diverse investment opportunities.” Translation: a basket of bonds so vanilla they could be served in a corporate cafeteria, wrapped in an expense ratio that never takes a day off. The issuer’s site also confirms that GLD and GLDM have filed registration statements with the SEC, which proves that State Street knows how to file filing trail but doesn’t necessarily prove that MYCG’s bonds are any tastier than the paper they’re printed on.

The fund’s operating structure is a three-layer State Street sandwich: SSGA Funds Management, Inc. acts as investment advisor; State Street Bank and Trust Company is the servicing agent; and State Street Global Markets, LLC-State Street’s own broker-dealer-is the distributor. That’s three entities, all owned by State Street, each taking a slice before your money even gets near a bond. The SEC EDGAR fund search confirms MYCG is a registered fund, but the real headline is the fee stack: 0.08% annually to hold a basket of bonds you could buy directly if you had the time and the credit desk.

State Street’s dividend distributions page confirms the fund pays for its own services and distribution, which is the financial equivalent of charging yourself to deposit your own cash. The fund’s AUM and liquidity figures are not disclosed in the supplied evidence, so we cannot say how many investors are actually buying the story. The Nasdaq listing confirms the ticker exists, but the evidence does not supply trading volume, bid-ask spreads, or recent price moves. The fund’s tracking method is index replication, but the evidence does not supply a tracking error history or performance versus benchmark. The FINRA Fund Analyzer link is provided, but the evidence does not supply a direct screenshot or figure. In short, the marketing is glossy, the fees are real, and the actual bonds are somewhere in the middle.

The chart route for MYCG is available on Nasdaq, but the evidence does not supply chart levels, volumes, or recent price action. The issuer’s sitemap lists MYCG as part of the SPDR family, but the evidence does not supply a prospectus page, holdings file, or recent annual report. The fund’s dividend policy is not specified in the evidence, so we cannot say when distributions occur or how much they might be. The fund’s top holdings and concentration limits are not supplied in the evidence, so we cannot say which BBB corporates are dominating the basket or how much of the fund is stuffed into any single issuer. The issuer’s claim of “diverse investment opportunities” remains unproven by the supplied evidence.